PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy

PepGen, Inc. announced approval by Health Canada of PepGen’s Clinical Trial Application (CTA) authorizing initiation of first-in-human trials of PepGen’s lead Enhanced Delivery Oligonucleotide (EDO) candidate, PGN-EDO51, to treat individuals with Duchenne muscular dystrophy.